



International Actuarial Association Health Section
2007 Colloquium

13th - 16th May 2007 Cape Town, South Africa

The Role of Risk Equalisation in Social and National Health Insurance

Professor Heather McLeod


Tuesday 15 May 2007

Agenda

- Transformation to Social Health Insurance
- Risk-Adjusted Cross-Subsidies
- Income Cross-Subsidies
- Moving from Voluntary to Mandatory Cover
- Impact of Chronic Disease on the Price of Healthcare
- Risk Equalisation using Chronic Disease
- Prevalence of Common Chronic Diseases

Transformation to Social Health Insurance


South African Population Pyramid



**Total population mid-2006 estimated to be 47.4 million people.
 42.6% are under age 20 and 61.5% are under age 30.
 Only 5.0% of the population are over age 65.**

Source: StatsSA Census 2001 and mid-year 2006 population estimate

Individual Income in South Africa




75.4% of the population do not earn any income.

40.3% live in a household where there is no-one who earns an income.


54.0% of the working age population do not earn any income.

Source: Extracted for DoSD using EPRI GHS 2005 data

Healthcare Inequality in SA



Source : ABSA Healthcare 2004



Source : adapted from Social Security Committee Report 2002 (Taylor Committee)

Early History of Health Cover in SA


- First “medical scheme”: De Beers Consolidated Mines Ltd. Benefit Society, established 1889. By 1910 seven schemes and by beginning of WWII 48 medical schemes.
- WHO: “A scheme for a national health service broadly similar to the British model was proposed in South Africa in 1944, comprising free health care and a network of community centres and general practitioners as part of a referral system, but was not implemented.”
- By 1960, 169 schemes covering nearly 1 million people – “urban, middle-class white population”. Coverage 80% of “eligible whites.”
- First Medical Schemes Act in 1967 ensured schemes were run on the basis of **solidarity** principles.
- By 1980, too many medical schemes with inadequate spread of risk. But pressure for more flexibility and less regulation. “Prevention of a “socialised health system” became a recurrent theme.
- Insurers became significantly involved in healthcare in early 1990s.

Sources: World Health Organization and Department of Health

Mutuality and Solidarity

- **Mutuality:** is the normal form of commercial insurance... Applicants contribute to the pool through a premium that relates to their particular risk at the time of the application, ... The pooled funds then pay those insured who suffer losses in accordance with the scale of their losses ...or in accordance with the agreed sum assured... A private commercial insurance market requires mutuality.
- **Solidarity:** is a concept that has some similarity to mutuality, but also a profound difference. The similarity is that losses are paid according to need, and the difference is that contributions are made not in accordance with the risks that each applicant brings .., but perhaps according to ability to pay, or just equally. Social security, social insurance or national insurance ... some measure of universality and some measure of compulsion.

Solidarity - Mutuality - Solidarity



A significant return to solidarity principles from 1 January 2000.

Solidarity - Mutuality - Solidarity

- DoH: “The history of the medical schemes movement and its regulation shows a drift from solidarity principles which defined the original schemes, to individualising health cover.”
- “By 1999 no open scheme was permitting anyone over the age of 55 to join as an individual member.” “Life-time exclusions for pre-existing conditions, and age-rating and/or experience rating of members.”
- “.. vulnerable groups excluded from cover (old and those with chronic conditions); medical costs continued to rise (due to retention of fee-for-service reimbursement); non-medical costs driven up (profit-taking and hidden commission costs).”
- The Melamet Commission reported in the last month of the apartheid government. Further deregulation recommended: “insurance products represented the best way of providing health cover”.
- Rejected by newly-elected democratic Government, replaced by strategic direction from 1995 National Health Insurance Committee of Inquiry: **Social Health Insurance** under solidarity principles.



National Health Act, 2003

- ... recognising the socio-economic injustices, imbalances and inequities of health services of the past
- ...the right of everyone of access to health services
- ...reasonable measures, within available resources to achieve the progressive realisation of these rights
- .. to establish a national health system which encompasses public, private and non-governmental providers of health services; ...

**Progress measured against goals of equity,
efficiency and access to the healthcare system**

Policy Flow in Medical Schemes since 1994


- Open enrolment
- Community rating
- Prescribed Minimum Benefits

Medical Schemes Act 1998 (effective January 2000)

- Replace private sector tax subsidy with per capita subsidy
- Risk-adjusted cross-subsidies to medical schemes
- Income cross-subsidies through social security tax
- Mandatory cover for all employed


Social Health Insurance

Future Healthcare Financing



Source: SHI Model Based on Census 2001

Coverage by Household Income



Source: SHI Model Based on Census 2001

Structure of South African Health System CURRENT

Revenue collection	General taxation	Social Insurance (RAF, COIDA)	Private insurance (medical schemes)	Out-of-pocket
Pooling	Provincial Health Departments			Other governmental
Purchasing		Private providers		
Provision				

Source: Ministerial Task Team on SHI 2005, using Kutzin framework

Structure of South African Health System

Social Health Insurance

Revenue collection	General taxation	Social Insurance (RAF, COIDA)	Social Insurance (payroll tax)	Out-of-pocket
Pooling	Provincial Health Departments		Risk Equalization Fund	No pooling (individual purchasing)
Purchasing			Private insurance (Medical Schemes)	
Provision			Other governmental	Private providers (including public hospitals)

Source: Ministerial Task Team on SHI 2005, using Kutzin framework

Structure of South African Health System

National Health Insurance

Revenue collection	National Insurance			Out-of-pocket	
Pooling	Provincial Health Departments	Other governmental	Social Insurance (RAF, COIDA)	Risk Equalization Fund	No pooling (individual purchasing)
Purchasing			Private insurance (Medical Schemes)		
Provision			Private providers (including public hospitals)		

Simple step from SHI to NHI: only a difference in revenue collection. However requires substantial increase in employment to be affordable.

Source: Ministerial Task Team on SHI 2005, using Kutzin framework

Risk-Adjusted Cross-Subsidies


Loss of Efficiency through Cream Skimming

- ◆ “The larger the predictable profits arising from cream skimming, the greater the chance that cream skimming will be more profitable than improving efficiency.”
- ◆ “At least in the short-run, when a health plan has limited resources available to invest in cost-reducing activities, it may prefer to invest in cream skimming rather than in improving efficiency... Efficient health plans, who do not cream skim applicants, may lose market share to inefficient health plans who do, resulting in a welfare loss to society.”
Van de Ven *et al* (March 1999, p.13)
- ◆ “Risk-equalisation should improve efficiency and reward those with lower costs.”
- ◆ “To achieve this risk-equalisation models must be based on objective risk factors or diagnostic information, not actual treatment, utilization or expenses incurred.”

Intention of the Risk Equalisation Fund (REF)

- ◆ The primary objective of the Risk Equalisation Fund in South Africa is to protect the environment of open enrolment and community rating.
- ◆ The purpose is to prevent competition between medical schemes from occurring on the basis of risk selection.
- ◆ In doing so it will encourage competition between medical schemes on the basis of cost and quality of healthcare delivery.

Social Health Insurance




Risk Definition

- Thus the REF will attempt to equalise the predictable financial consequences that are introduced to the medical schemes environment in view of the requirements of community rating, open enrolment and PMBs.
- In the context of the REF, risk is defined as:
 - the expected and predictable significant deviation from the theoretical national community-rated price for groups of beneficiaries with a measurable set of risk factors
 - the national community-rated price is the reasonably efficient achievable price for the common set of benefits.



Source : FCTT, 14 October 2003

Price by Age and Components for Prescribed Minimum Benefits




DTP Hospital covers some 290 diagnosis-treatment pairs, largely hospital-based. CDL Medicine covers medicine for 25 chronic conditions and HIV/AIDS. Related costs is out-of-hospital care and diagnosis for the above.


Source: REF Contribution Table 2007



Age Profiles Largest Open Schemes




Amount pbpm Payable to REF



Industry Community Rate for March 2006 is R224.90



Isolated REF in Shadow Period



Risk Factors in Formula

- **Age**
- **Deliveries**
- **Gender** (from 2007)
- Not ethnicity. Not geographic region
- Not open/restricted scheme
- Not primary member, marital status or family size
- Not income
- **Measures of chronic disease burden:**
 - **Numbers with each CDL disease**
 - **Numbers with multiple CDL diseases**
 - **Numbers with HIV/AIDS on ARV therapy**
- Not high cost, low frequency conditions.



Source: FCTT 5 November 2003; RETAP 2007

REF Contribution Table

[Base 2005, Use 2007]

REF Contribution Table [Base 2005, Use 2007]																
Per Beneficiary Per Month																Expected Industry REF Community Rate
																257.05
																The actual Industry Community Rate for each payment period is determined according to the REF Grids that are approved for shadow payments.
Age Bands	No CDL Diseases NON	Chronic Disease List (CDL) Conditions														
		ADS	AST	BCE	BMD	CHF	CMY	COP	CRF	CSD	DBI	DM1	DM2	DYS	EPL	GLC
Column	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
Under 1	505.04															
1-4	87.62	234.97	391.53	551.32	1,266.05	1,267.57	1,267.57	1,459.04	15,986.75	1,293.86	921.26	1,505.94	535.45	693.80	795.78	311.50
5-9	40.45	187.80	344.35	504.15	1,218.88	1,220.39	1,220.39	1,411.87	15,939.57	1,246.68	874.09	1,458.76	488.27	646.63	748.61	264.33
10-14	37.41	184.76	341.31	501.11	1,215.84	1,217.35	1,217.35	1,408.83	15,936.54	1,243.64	871.05	1,455.71	485.23	643.59	745.57	261.28
15-19	55.41	202.76	359.33	519.11	1,233.84	1,235.36	1,235.36	1,426.83	15,954.53	1,261.65	889.05	1,473.71	503.23	661.59	763.57	279.28
20-24	87.76	235.11	391.66	551.46	1,266.19	1,267.71	1,267.71	1,459.18	15,986.89	1,294.00	921.40	1,506.06	535.57	693.94	795.92	311.63
25-29	123.63	270.98	427.53	587.33	1,302.04	1,303.57	1,303.57	1,495.05	16,022.74	1,329.87	957.27	1,541.93	571.44	729.80	831.78	347.50
30-34	142.63	289.99	446.55	606.34	1,321.06	1,322.59	1,322.59	1,514.05	16,041.76	1,348.87	976.27	1,560.94	590.45	748.81	850.80	366.51
35-39	295.36	313.41	470.05	611.71	1,326.44	1,327.96	1,327.96	1,519.43	16,047.14	1,354.25	981.65	1,566.31	595.83	754.19	856.17	371.88
40-44	166.14	313.41	470.05	629.85	1,344.56	1,346.09	1,346.09	1,537.56	16,065.26	1,372.38	999.78	1,584.45	613.96	772.32	874.31	390.02
45-49	340.17	340.17	500.00	656.52	1,371.25	1,372.77	1,372.77	1,564.24	16,091.95	1,399.06	1,026.46	1,611.14	640.65	799.00	900.98	416.70
50-54	243.13	390.48	547.03	706.82	1,421.55	1,423.07	1,423.07	1,614.54	16,142.24	1,449.36	1,076.77	1,661.42	690.94	849.30	951.28	466.99
55-59	312.98	460.33	616.89	776.69	1,491.40	1,492.93	1,492.93	1,684.40	16,212.10	1,519.22	1,146.62	1,731.29	760.80	919.16	1,021.15	536.86
60-64	421.34	568.69	725.26	885.05	1,599.77	1,601.29	1,601.29	1,792.76	16,320.47	1,627.59	1,254.98	1,839.65	869.17	1,027.52	1,129.51	645.22
65-69	527.24	674.59	831.15	990.94	1,705.66	1,707.19	1,707.19	1,898.66	16,426.36	1,733.48	1,360.88	1,945.54	975.06	1,133.41	1,235.40	751.11
70-74	606.36	753.71	910.26	1,070.06	1,784.79	1,786.30	1,786.30	1,977.77	16,505.49	1,812.59	1,440.00	2,024.66	1,054.18	1,212.54	1,314.52	830.23
75-79	645.30	792.65	949.22	1,109.01	1,823.73	1,825.26	1,825.26	2,016.72	16,544.43	1,851.54	1,478.94	2,063.61	1,093.13	1,251.48	1,353.47	869.18
80-84	596.89	744.24	900.80	1,060.60	1,775.31	1,776.84	1,776.84	1,968.31	16,496.01	1,803.13	1,430.53	2,015.20	1,044.71	1,203.07	1,305.06	820.76
85+	534.18	681.53	838.11	997.89	1,712.61	1,714.14	1,714.14	1,905.60	16,433.31	1,740.43	1,367.82	1,952.49	982.01	1,140.36	1,242.34	758.06

Combined Female and Male Tables for Comparison

												HIV/ AIDS
HAE	HYL	HYP	IBD	IHD	MSS	PAR	RHA	SCZ	SLE	TDH	HIV	
17	18	19	20	21	22	23	24	25	26	27	28	
10,815.39	312.80	257.26	514.11	943.30	9,013.45	976.71	453.66	727.06	1,342.03	170.86	1,084.96	
10,768.22	265.62	210.09	466.94	896.12	8,966.27	929.54	406.48	679.89	1,294.85	123.69	1,037.77	
10,765.18	262.58	207.05	463.90	893.08	8,963.23	926.50	403.44	676.85	1,291.81	120.64	1,034.74	
10,783.17	280.59	225.05	481.90	911.08	8,981.23	944.49	421.45	694.85	1,309.82	138.65	1,052.75	
10,815.53	312.93	257.41	514.26	943.42	9,013.58	976.85	453.79	727.20	1,342.17	171.00	1,085.09	
10,851.40	348.80	293.28	550.13	979.29	9,049.45	1,012.72	489.65	763.07	1,378.04	206.87	1,120.96	
10,870.40	367.82	312.28	569.13	998.30	9,068.46	1,031.72	508.68	782.08	1,397.04	225.88	1,139.97	
10,875.77	373.19	317.65	574.50	1,003.69	9,073.83	1,037.10	514.05	787.45	1,402.42	231.25	1,145.35	
10,893.91	391.31	335.79	592.64	1,021.81	9,091.96	1,055.23	532.17	805.59	1,420.55	249.39	1,163.47	
10,920.59	418.00	362.46	619.31	1,048.50	9,118.65	1,081.91	558.86	832.26	1,447.23	276.06	1,190.16	
10,970.89	468.30	412.77	669.62	1,098.78	9,168.94	1,132.21	609.16	882.57	1,497.53	326.36	1,240.46	
11,040.75	538.15	482.63	739.48	1,168.65	9,238.80	1,202.07	679.01	952.43	1,567.39	396.23	1,310.31	
11,149.11	646.51	590.99	847.84	1,277.02	9,347.16	1,310.43	787.38	1,060.79	1,675.76	504.59	1,418.68	
11,255.01	752.41	696.89	953.74	1,382.90	9,453.06	1,416.33	893.28	1,166.69	1,781.65	610.48	1,524.58	
11,334.12	831.53	776.00	1,032.85	1,462.03	9,532.17	1,495.45	972.39	1,245.80	1,860.76	689.60	1,603.69	
11,373.07	870.48	814.95	1,071.80	1,500.97	9,571.13	1,534.39	1,011.35	1,284.75	1,899.71	728.55	1,642.65	
11,324.66	822.06	766.54	1,023.39	1,452.56	9,522.71	1,485.98	962.92	1,236.34	1,851.30	680.14	1,594.22	
11,261.95	759.36	703.83	960.68	1,389.86	9,460.01	1,423.27	900.22	1,173.62	1,788.60	617.43	1,531.53	

Modifier for number of chronic conditions

Number of Conditions	2	3	4 or more
	CC2	CC3	CC4
All Ages	194.88	532.95	1,074.78

Amount is per beneficiary per month.
Add to amounts obtained from Columns 1 to 28.
Not applicable to Under 1's.

Modifier for Maternity

	MAT
All Ages	17,515.39

Amount is per beneficiary (per month).
Use only once per delivery, not monthly.


RETAP

REF Grids in Shadow Period

- The **REF Grid Count** gives the cell to which each beneficiary in the option is allocated. The total number of beneficiaries sums to the number in the option. This table is used to obtain the amount payable by the REF to the scheme.
- The **REF Grid Prevalence** gives the prevalence of each condition. For example a beneficiary with asthma and hypertension is counted in both columns. The total therefore exceeds the number of beneficiaries in the option by the extent of multiple CDL conditions. This table is used for research purposes and to enable comparison of prevalences to published medical literature.

RETAP

Haemophilia Rate per 1,000



Over-reporting of HAE by 9 schemes resolved.


Problems with one scheme remain.

Risk
Equalisation
Fund




Income Cross-Subsidies


Universal Per Capita Subsidy



Problems with Current Pillar 1 Subsidy for Healthcare




DoH Proposal: Restructured Pillar 1 Subsidy for Healthcare



In the private sector the subsidy is used for the Prescribed Minimum Benefit package, redefined to include primary care (the Basic Benefit Package or BBP).

Social Health Insurance




Phased Implementation of SHI

- **Current Situation**
 - 6.9 million people. Health tax equivalent: 1.2%
- **Scenario 2: Restructure Pillar 1 Subsidy**
 - Up to 8.3 million people. Health tax equivalent: 1.5%
- **Scenario 3: Social Health Insurance Phase 1**
 - 10.5 million people. Health tax equivalent: 3.1%
- **Scenario 4: Social Health Insurance Phase 2**
 - 13.4 million people. Health tax equivalent: 4.1%
- **Scenario 5: National Health Insurance**
 - Total population. Health tax equivalent: 14.3%
 - NHI is not affordable

Mandatory Contributions


- International Review Panel: split the idea of “mandatory membership” from that of “mandatory contributions”.
- SHI flow of funds envisages mandatory contributions.
- Need to use SARS (tax authorities) to determine income and to collect contributions to SHI.
- **Mandatory membership** could follow some years later but may not be essential.

Summary of Mandatory Impact as a Percentage of Family Income



Source: Analysis for Ministerial Task Team on SHI


Policy Objective and Trajectory



Source: MTT July 2005

**Voluntary to
Mandatory Cover**


Anti-Selection in Maternity Years



Significant female anti-selection in child-bearing years.

Source: StatsSA and REF, mid-year 2006


Anti-selection by Age



Far fewer children and young adults, many more late working age and older lives if full NHI. For SHI, need to consider effect using income bands.

Source: StatsSA and REF, mid-year 2006


Medical Scheme Membership by Individual Income



Clear and strong pattern of membership by income.

Source: EPRI GHS2005


Medical Scheme Membership by Highest Household Income



Clear and strong pattern of membership by Household income.

Source: EPRI GHS2005


Age Profile Potential SHI



Under SHI, many young adults would be included. Whole tail would become younger.

Source: StatsSA and REF, mid-year 2006; EPRI GHS2005 income patterns


Impact on Community Rate of Mandatory Membership



Price of PMBs falls by some 10% on age and gender effects alone. Price falls by some 20% if effects of anti-selection included.

Source: StatsSA and REF, mid-year 2006; EPRI GHS2005 income patterns

Impact on Community Rate of Mandatory Membership




Effects shown in Rand terms.

Source: StatsSA and REF, mid-year 2006; EPRI GHS2005 income patterns

Impact of Chronic Disease on the Price of Healthcare


Prevalence of Chronic Disease



Source: REF Contribution Table 2007




Prevalence by Age of Chronic Disease



Source: REF Contribution Table 2007




Proportion of Chronic Disease by Age



Source: REF Contribution Table 2007




Price by Age of Chronic Disease



Source: REF Contribution Table 2007




Proportion of Price by Age



Source: REF Contribution Table 2007



Price by Age of Chronic Disease




The burden of heart disease is clear.

Source: REF Contribution Table 2007




Chronic Disease in Price of PMBs



Source: REF Contribution Table 2007




Price by Age of Chronic Disease Using HIV/AIDS Prevalence in 2010



Source: REF Contribution Table 2006




Components of PMB Price by Age



Source: REF Contribution Table 2007



Components of PMB Price



Source: REF Contribution Table 2007




Risk Equalisation using Chronic Disease

Concept of “Treated Patient”

- Because the REF is fundamentally based on financial risk rather than medical risk, the entry criteria/definition should be aimed at the “treated patient” rather than the early or “pre-clinical stages” of a medical condition; and
- That the definitions/entry criteria would primarily be used for new patients while currently treated chronic medical scheme patients will not be subjected to these criteria – e.g. it would be medically irresponsible to stop a well-controlled HIV/AIDS, hypertensive or cardiac failure patient’s treatment to prove that he/she meets the REF definition/entry criteria.

Role of Entry and Verification Criteria for REF



Definition of TREATED and CASES

- ◆ Two sets of data were extracted:
 - ◆ The first used the full Entry and Verification definitions and was called the “Treated Patient Data set” or “**TREATED**”
 - ◆ The second set was extracted without the test for “treated patient” and was called the “Total Cases Data set” or “**CASES**”.
- ◆ While this meant a doubling of the extractions, it provided a powerful tool to investigate potential prevalence and cost if compliance improves and to be able to determine the impact if more people in future fall within the definition of “treated patient”.
- ◆ Most important comparison for REF financial sensitivity is **CASES Count** vs. **TREATED Count**. Difference represents “bubbling under” for each disease.

Table 17: Hypertension

Hypertension						
For count purposes, only one of the following cardiovascular diseases can be assigned to the same patient: <i>Cardiomyopathy and Cardiac Failure, Coronary Artery Disease, Dysrhythmias; and Hypertension</i>						
For count purposes, only one of <i>Hypertension or Chronic Renal Disease</i> may be assigned to the same patient						
Diagnosis-related information		Proof of Treatment				
Provider code of the diagnosing provider	ICD10 Codes (Any of the following)	Evidence of payment of claims for any product included in the ATC categories below, in two different calendar months in the three calendar months preceding the current month:				
Any registered medical practitioner	AND	I10	I15.0	AND	C02	C08
		I11	I15.1		C03	C09
		I11.0	I15.2		C07	G04CA03
		I11.9	I15.8			
		I12	I15.9			
		I12.0	O10			
		I12.9	O10.0			
		I13	O10.1			
		I13.0	O10.2			
		I13.1	O10.3			
		I13.2	O10.4			
		I13.9	O10.9			
		I15	O11			

CASES and TREATED

TREATED requires Proof of Treatment

Hypertension	
C02	ANTIHYPERTENSIVES
C03	DIURETICS
C07	BETA BLOCKING AGENTS
C08	CALCIUM CHANNEL BLOCKERS
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
G04CA03	Terazosin

Amended April 2007 to use “treatment month” not “payment month” as the latter is being gamed.

It is possible to spread payment for a multi-line script over two months and hence more people are identified as “treated patients”.



Ranking of Diseases in Multiple Disease Rules


- ◆ Effectively uses an approach similar to hierarchical co-existing conditions methodology.
- ◆ Order of diseases from REFCT2007 using gender as a risk factor.
- ◆ Only one disease in the following groups may be selected. Highest cost disease in **bold**:
 - ◆ respiratory: **COP**+AST+BCE
 - ◆ cardiac: **CMY**+CHF+IHD+DYS+HYP
 - ◆ renal: **CRF**+HYP
 - ◆ gastro: **CSD**+IBD
 - ◆ diabetes: DM1+**DM2** (always default to DM2)
 - ◆ mental: **BMD**+SCZ
 - ◆ neuro: **MSS**+BMD+EPL
 - ◆ skeletal: **SLE**+RHA (other way around in REF Study 2002)

Source: REF Study 2005



Hypertension (HYP)

Hypertension		Tables published with REFCT 2007
Rate per 1,000 Lives	CASES Prevalence and Count	



All with HYP diagnosis

After cardiac and renal multiple rules

Allocation to highest cost disease. Potential HYP count if compliance improves.

REF Grid Count and REF payments: "treated patient"

Impact of renal and cardiac rules at older ages.


cardiac: CMY+CHF+IHD+DYS+HYP

renal: CRF+HYP

Source: REF Study 2005



Price by Age of Chronic Disease




Industry Community Rate for PMBs is R257.05 pbpm

Source: REF Contribution Table 2007



Impact if all Chronic become Verified




Industry Community Rate increases from R257.05 to R332.75 pbpm

Source: REF Contribution Table 2007



Sensitivity of the REF Table


- ◆ The Community Rate would be highly unlikely to reach the higher levels. As more chronic people become “treated patients”, so the values for each disease should be altered to be closer to the CASES results.
- ◆ The average cost comes down as people are added with less serious disease.
- ◆ This is a timing issue – the adjustment to the REF Table takes place annually while there could be an increase in the number of “treated patients” during the year.
- ◆ Schemes only need to consider changes in industry numbers of “treated patients” during a year, until the next revision of the REF Table.



Prevalence of Chronic Disease

Hypertension Prevalence

**TREATED
Verified**




Impact of renal and cardiac multiple rules at older ages.

Source: REF Study 2005



Hyperlipidaemia Prevalence

**TREATED
Verified**




Not included in cardiac multiple rule. Levels similar to 2002. Predominantly male.

Source: REF Study 2005



Cardiomyopathy and Cardiac Failure Prevalence

**TREATED
Verified**



Diseases now combined but prevalence exceeds CHF+CMY in 2002.

Source: REF Study 2005




Asthma Prevalence

**TREATED
Verified**

Tables published with REFCT 2007

Asthma	Rate per 1,000 Lives	TREATED	Revised Prevalence
--------	----------------------	---------	--------------------




Predominantly male in childhood, female in adult years.

Source: REF Study 2005



COPD Prevalence

**TREATED
Verified**




Late onset. Predominantly male.

Source: REF Study 2005



Diabetes Type 2 Prevalence

**TREATED
Verified**



Similar to previous levels. Predominantly male.


Source: REF Study 2005



Advice on Developing a Risk Equalisation System

- Obtain clear objectives for the healthcare system and RE
- Define and price a common benefit package
- Choose broad methodology and check economic impact
- Set criteria for risk factors
- Research and determine impact of risk factors
- Determine formula
- Peer review: local and international
- Implementation issues: governance, accounting, timing, data flows, money flows, legislation, politics ...

● **Consult, consult, consult**



International Actuarial Association Health Section
2007 Colloquium

13th - 16th May 2007 **Cape Town, South Africa**

IAAHS 2007

IAA Health Section Colloquium

13th – 16th May 2007

CTICC

www.iaahs2007.com

Professor Heather McLeod

hmcleod@iafrica.com